Codexis(US:CDXS)2026-03-11 21:32Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [21] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [21] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, up from 56% in the prior year [22] - Net income for Q4 2025 was $9.6 million, compared to a net loss of $10.4 million in Q4 2024; net loss for the full year 2025 was $44 million, improved from a loss of $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin, with stabilization in revenue, supported by a robust pipeline of drugs in late-stage clinical studies [10] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling production to 100 grams, with plans to reach half a kilo by the end of 2026 [6][7] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in five years is estimated to be $2 billion, with a growing demand for siRNA medicines at a rate of 5%-10% per year [5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [57] Company Strategy and Development Direction - The company is focused on establishing itself as a key technology provider in the RNA medicine market through its ECO Synthesis platform, which aims to address challenges in siRNA production [4][5] - Plans include scaling up production capabilities, achieving GMP certification, and expanding partnerships with CDMOs to enhance manufacturing processes [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the ECO Synthesis platform and the overall siRNA market, highlighting the importance of innovation and customer collaboration [12][28] - The company aims to demonstrate proof of success through new contracts and licensing deals in 2026, while maintaining a focus on financial performance and expense management [27][29] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value of stereoisomer control - Management is actively exploring the biological activity of stereo configurations and plans to present data at the TIDES USA meeting, with several customers interested in collaboration [31][32] Question: Understanding the recent deal process - The recent deal involved a small organization with a cardiovascular asset, highlighting the long-term discussions and mutual excitement about the ECO Synthesis platform's capabilities [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, with expectations that successful data will lead to IND submissions and larger contracts for clinical trials [41][43] Question: Revenue guidance visibility - Management indicated a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, though some estimates remain speculative at the beginning of the year [50][51] Question: Growth expectations for biocatalysis business - The small molecule biocatalysis business is expected to stabilize and continue to fuel growth, while higher growth rates are anticipated from the ECO side of the business [62][65]